Synthetic molecules as DprE1 inhibitors: A patent review

Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3

(2020) Giulia Degiacomi et al.   Applied Sciences-Basel

OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor

(2020) Norimitsu Hariguchi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New tuberculosis drug targets, their inhibitors, and potential therapeutic impact

(2020) Gauri S. Shetye et al.   Translational Research

Development of Macozinone for TB treatment: An Update

(2020) Vadim Makarov et al.   Applied Sciences-Basel

The main results of clinical trials of the efficacy, safety and pharmacokinetics of the perspective anti-tuberculosis drug makozinone (PBTZ169)

(2020) A. O. Mariandyshev et al.   TERAPEVTICHESKII ARKHIV

Diagnostic Potential of IgG and IgA Responses to Mycobacterium tuberculosis Antigens for Discrimination among Active Tuberculosis, Latent Tuberculosis Infection, and Non-Infected Individuals

(2020) Ji Yeon Lee et al.   Microorganisms

Two Decades of TB Drug Discovery Efforts—What Have We Learned?

(2020) Balachandra Bandodkar et al.   Applied Sciences-Basel

Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis

(2020) Suma KB et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Pretomanid: First Approval

(2019) Susan J. Keam   DRUGS

Recent updates on drug resistance in Mycobacterium tuberculosis

(2019) R. Singh et al.   JOURNAL OF APPLIED MICROBIOLOGY

Decaprenyl-phosphoryl-ribose 2′-epimerase (DprE1): challenging target for antitubercular drug discovery

(2018) Jineetkumar Gawad et al.   Chemistry Central Journal

Drug discovery in tuberculosis. New drug targets and antimycobacterial agents

(2018) André Campaniço et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Tuberculosis treatment

(2017) Marcelo Fouad Rabahi et al.   Jornal Brasileiro de Pneumologia

New agents for the treatment of drug-resistant Mycobacterium tuberculosis

(2016) Daniel T. Hoagland et al.   ADVANCED DRUG DELIVERY REVIEWS

Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis

(2016) Ameeruddin Nusrath Unissa et al.   INFECTION GENETICS AND EVOLUTION

Traitement de la tuberculose

(2015) J. Ben Amar et al.   Revue de Pneumologie Clinique

DprE1 - from the Discovery to the Promising Tuberculosis Drug Target

(2014) Katarina Miku.sova et al.   CURRENT PHARMACEUTICAL DESIGN

The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis

(2013) Giovanna Riccardi et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Treatment of latent tuberculosis infection

(2013) Madhavi J. Parekh et al.   Therapeutic Advances in Respiratory Disease

RETRACTED ARTICLE: Antituberculars which target decaprenylphosphoryl-β-D-ribofuranose 2′-oxidase DprE1: state of art

(2012) Silvia Buroni et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Benzothiazinones: Prodrugs That Covalently Modify the Decaprenylphosphoryl-β-d-ribose 2′-epimerase DprE1 ofMycobacterium tuberculosis

(2010) Claudia Trefzer et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Novel targets in M. tuberculosis: search for new drugs

(2010) Gyanu Lamichhane   TRENDS IN MOLECULAR MEDICINE

Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

(2009) V. Makarov et al.   SCIENCE